The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial
Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and γ-glutamylcysteine (γ-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and γ-glutamylcysteine (γ-...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cosmetics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9284/10/3/72 |
| _version_ | 1797595378376245248 |
|---|---|
| author | Yoshiaki Uchida Tomomi Kaneda Mio Ono Masao Matsuoka Utano Nakamura Akiko Ishida Yoshimitsu Yamasaki Hiroki Takeo Takanobu Sakurai |
| author_facet | Yoshiaki Uchida Tomomi Kaneda Mio Ono Masao Matsuoka Utano Nakamura Akiko Ishida Yoshimitsu Yamasaki Hiroki Takeo Takanobu Sakurai |
| author_sort | Yoshiaki Uchida |
| collection | DOAJ |
| description | Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and γ-glutamylcysteine (γ-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and γ-glutamylcysteine (γ-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: <i>n</i> = 16, 90 mg: <i>n</i> = 15, and placebo: <i>n</i> = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (<i>p</i> = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness. |
| first_indexed | 2024-03-11T02:35:34Z |
| format | Article |
| id | doaj.art-2a2fed47d7a845d9838f1f7b863c895b |
| institution | Directory Open Access Journal |
| issn | 2079-9284 |
| language | English |
| last_indexed | 2024-03-11T02:35:34Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cosmetics |
| spelling | doaj.art-2a2fed47d7a845d9838f1f7b863c895b2023-11-18T09:54:57ZengMDPI AGCosmetics2079-92842023-05-011037210.3390/cosmetics10030072The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical TrialYoshiaki Uchida0Tomomi Kaneda1Mio Ono2Masao Matsuoka3Utano Nakamura4Akiko Ishida5Yoshimitsu Yamasaki6Hiroki Takeo7Takanobu Sakurai8Research and Development Division, Mitsubishi Corporation Life Sciences Limited, 1-1-3 Yurakucho, Chiyoda-ku, Tokyo 100-0006, JapanResearch and Development Division, Mitsubishi Corporation Life Sciences Limited, 1-1-3 Yurakucho, Chiyoda-ku, Tokyo 100-0006, JapanResearch and Development Division, Mitsubishi Corporation Life Sciences Limited, 1-1-3 Yurakucho, Chiyoda-ku, Tokyo 100-0006, JapanM&I Science CORP, 1-17-26 Nakatsu, Kita-ku, Osaka-shi 531-0073, JapanPharma Foods International Co., Ltd., 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245, JapanPharma Foods International Co., Ltd., 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245, JapanNISHI-UMEDA Clinic for Asian Medical Collaboration, 3-3-45 Umeda, Kita-ku, Osaka 530-0001, JapanMedical Corporation Diastep TAKEO Clinic, 4-22-7 Taishido, Setagaya-ku, Tokyo 154-0004, JapanResearch and Development Division, Mitsubishi Corporation Life Sciences Limited, 1-1-3 Yurakucho, Chiyoda-ku, Tokyo 100-0006, JapanGlutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and γ-glutamylcysteine (γ-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and γ-glutamylcysteine (γ-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: <i>n</i> = 16, 90 mg: <i>n</i> = 15, and placebo: <i>n</i> = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (<i>p</i> = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness.https://www.mdpi.com/2079-9284/10/3/72cysteine peptideglutathionecysteinylglycineγ-glutamylcysteineskin brightnesssafety |
| spellingShingle | Yoshiaki Uchida Tomomi Kaneda Mio Ono Masao Matsuoka Utano Nakamura Akiko Ishida Yoshimitsu Yamasaki Hiroki Takeo Takanobu Sakurai The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial Cosmetics cysteine peptide glutathione cysteinylglycine γ-glutamylcysteine skin brightness safety |
| title | The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial |
| title_full | The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial |
| title_fullStr | The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial |
| title_full_unstemmed | The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial |
| title_short | The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial |
| title_sort | effect of cysteine peptide ingestion on skin brightness a randomized double blind placebo controlled parallel group human clinical trial |
| topic | cysteine peptide glutathione cysteinylglycine γ-glutamylcysteine skin brightness safety |
| url | https://www.mdpi.com/2079-9284/10/3/72 |
| work_keys_str_mv | AT yoshiakiuchida theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT tomomikaneda theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT mioono theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT masaomatsuoka theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT utanonakamura theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT akikoishida theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT yoshimitsuyamasaki theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT hirokitakeo theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT takanobusakurai theeffectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT yoshiakiuchida effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT tomomikaneda effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT mioono effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT masaomatsuoka effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT utanonakamura effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT akikoishida effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT yoshimitsuyamasaki effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT hirokitakeo effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial AT takanobusakurai effectofcysteinepeptideingestiononskinbrightnessarandomizeddoubleblindplacebocontrolledparallelgrouphumanclinicaltrial |